Mometason Glenmark (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors inside skin cells, altering gene transcription. This suppresses the production of inflammatory mediators, reduces immune‑cell migration, and stabilises lysosomal membranes, leading to decreased swelling, erythema and itching at the site of application.

The specific dosing regimen is determined by the prescribing clinician based on the severity of the condition, the area of skin involved and patient factors. Typically, a thin layer is applied once or twice daily to the affected area, but exact instructions must come from a qualified health professional.

Safety data for topical mometasone furoate during pregnancy and lactation are limited. The product should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made in consultation with a healthcare provider.

To request supply, visit the product page on gnhindia.com, submit an enquiry with the required quantity, and provide institutional or trade credentials. GNH India’s commercial team will verify eligibility, then respond with pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Mometasone furoate is classified as a high‑potency corticosteroid, offering stronger anti‑inflammatory effects than low‑potency agents such as hydrocortisone. Compared with other high‑potency options like betamethasone dipropionate, mometasone provides similar efficacy with a favorable safety profile when used as directed.

Store the product at room temperature, below 25 °C, in its original packaging. Protect it from moisture, direct sunlight and excessive heat. Keep the container tightly closed and out of reach of children.

Apply a thin, even layer of the cream or ointment to clean, dry skin on the affected area. Gently rub it in until fully absorbed, usually once or twice daily as prescribed. Avoid contact with eyes, mucous membranes and broken skin unless directed by a clinician.

Serious adverse events, though rare, include skin atrophy, hypopigmentation, secondary infections, systemic adrenal suppression with extensive use, and severe allergic reactions such as contact dermatitis or urticaria. Patients should report any unusual skin changes or systemic symptoms promptly.

The product is contraindicated in individuals with known hypersensitivity to mometasone furoate or any formulation excipients, and in patients with untreated fungal, bacterial or viral skin infections in the area to be treated. Caution is also advised for patients with severe skin thinning or those requiring long‑term systemic corticosteroid therapy.